Jeffrey S Weber (Jeffrey Weber, Tatsuya Yoshida)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 29

Top Topics

Top Venues

Journal for immunotherapy of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey S Weber, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Georgina V Long, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, James M G Larkin
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman, Jeffrey M Clarke, Ricklie Julian, Aaron James Scott, Jessica L Geiger, Kedar S Kirtane, Celine Robert-Tissot, Brandon Coder, Moomal Tasneem, Jing Sun, Wei Zheng, Lauren Gerbereux, Andressa Laino, Filippos Porichis, Jack Pollard, Peijie Hou, Vasudha Sehgal, Xing Chen, Manju Morrissey, Hikmat N Daghestani, Igor Feldman, Lakshmi Srinivasan, Joshua P Frederick, Michelle Brown, Praveen Aanur, Robert Meehan, Howard A Burris
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer discovery (2024)
Kelsey R Monson, Robert Ferguson, Joanna E Handzlik, Jiahan Xiong, Sasha Dagayev, Leah J Morales, Vylyny Chat, Anabelle Bunis, Chaitra Sreenivasaiah, Sonia Dolfi, Daniel J Tenney, Yongzhao Shao, Iman Osman, Jeffrey S Weber, Tomas Kirchhoff
Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kelsey R Monson, Robert Ferguson, Joanna E Handzlik, Jiahan Xiong, Sasha Dagayev, Leah J Morales, Vylyny Chat, Anabelle Bunis, Chaitra Sreenivasaiah, Sonia Dolfi, Daniel J Tenney, Yongzhao Shao, Iman Osman, Jeffrey S Weber, Tomas Kirchhoff
Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey S Weber, Laura C Cappelli
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Journal for immunotherapy of cancer 11 (3) (2023)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S Weber, John V Heymach
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer 11 (3) (2023)
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Kaysia Ludford, Emma J Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A Sparks, Osama Abu-Shawer, Osama Rahma, Uma Thanarajasingam, Ashley M Zeman, Rafee Talukder, Namrata Singh, Sarah H Chung, Petros D Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey S Weber, Jean H Tayar, Maria E Suarez-Almazor, Noha Abdel-Wahab, Adi Diab
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. Journal for immunotherapy of cancer 11 (6) (2023)
Ankita Mitra, Brian Thompson, Ann Strange, Carol M Amato, Melinda Vassallo, Igor Dolgalev, Jonathan Hester-McCullough, Tomoaki Muramatsu, Diana Kimono, Amrutesh S Puranik, Jeffrey S Weber, David M Woods
A Population of Tumor-Infiltrating CD4+ T-cells Co-expressing CD38 and CD39 is Associated with Checkpoint Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S Weber, John V Heymach
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer 11 (3) (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S Weber, John V Heymach
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer 11 (3) (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo Antonio Ascierto, Michael B Atkins, Kathryn Bollin, Matías Chacón, Nancy B Davis, Mark B Faries, Pauline Funchain, Jason S Gold, Samantha Guild, David E Gyorki, Varinder Kaur, Nikhil I Khushalani, Joanne M Jeter, Jennifer Leigh McQuade, Michael O Meyers, Anthony Provenzano, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K Sondak, Gilliosa Spurrier, Umang Swami, Thach-Giao Truong, Katy K Tsai, Alexander C J van Akkooi, Jeffrey S Weber
Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric D Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q Phan, John M Kirkwood, Jessica C Hassel, Marlana Orloff, James Larkin, Jeffrey S Weber, Andrew J S Furness, Nikhil I Khushalani, Theresa Medina, Michael E Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A Sarnaik
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer 10 (12) (2023)
James M G Larkin, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Mark Ross Middleton, Jose Lutzky, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew G Hill, Leslie A Fecher, Michael Millward, Paul D Nathan, Nikhil I Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo Antonio Ascierto, Jeffrey S Weber
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney, Ragini Kudchadkar, Joseph Markowitz, Andrew S Brohl, Anna Pavlick, Alison Richards, David M Woods, Jeffrey S Weber
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer 10 (11) (2022)
Salman R Punekar, Jeffrey S Weber
Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (23) (2022)
Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer immunology, immunotherapy : CII (2022)
Jeffrey S Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al . Journal for immunotherapy of cancer 10 (1) (2022)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, James M G Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen J Gogas, Stéphane Dalle, Nicolas Meyer, Paolo Antonio Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C Hassel, Caroline Robert, Matteo S Carlino, Anna Maria Di Giacomo, Marcus O Butler, Eva Muñoz Couselo, Michael P Brown, Piotr Lukasz Rutkowski, Andrew M Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz Merino, Andre van der Westhuizen, Alexander M Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J Tenney, Hao Tang, Georgina V Long
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Mario Mandala, James Larkin, Paolo Antonio Ascierto, Michele Del Vecchio, Helen J Gogas, C Lance Cowey, Ana Arance, Stéphane Dalle, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Jose Lutzky, Luis De La Cruz-Merino, Victoria Atkinson, Petr Arenberger, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil I Khushalani, Veerle de Pril, Maurice Lobo, Jeffrey S Weber
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. Journal for immunotherapy of cancer 9 (8) (2022)
Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer immunology, immunotherapy : CII (2022)
MacLean S Hall, John E Mullinax, Cheryl A Cox, Amy M Hall, Matthew S Beatty, Jamie Blauvelt, Patrick Innamarato, Luz E Nagle, Holly Branthoover, Doris Wiener, Benjamin I Schachner, Alberto J Martinez, Allison D Richards, Carolyn J Rich, Marjorie Colón Colón, Michael J Schell, Jamie K Teer, Nikhil I Khushalani, Jeffrey S Weber, James J Mule, Vernon K Sondak, Shari A Pilon-Thomas, Amod A Sarnaik
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marianne J Davies, Marc S Ernstoff, Leslie A Fecher, Monalisa Ghosh, Ishmael Jaiyesimi, Jennifer S R Mammen, Aung Naing, Loretta J Nastoupil, Tanyanika Phillips, Laura D Porter, Cristina A Reichner, Carole Seigel, Jung-Min Song, Alexander I Spira, Maria E Suarez-Almazor, Umang Swami, John A Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S Weber, Pauline Funchain, Kathryn Bollin
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina, Harriet M Kluger, Sajeve S Thomas, Evidio Domingo-Musibay, Anna C Pavlick, Eric D Whitman, Salvador Martin-Algarra, Philippa Corrie, Brendan D Curti, Judit Oláh, Jose Lutzky, Jeffrey S Weber, James M G Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cecile Chartier, Friedrich Graf Finckenstein, Maria Fardis, Joanne M Jeter, Jason A Chesney
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Bianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J Schneider, Milan Anadkat, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marianne J Davies, Marc S Ernstoff, Leslie A Fecher, Pauline Funchain, Ishmael Jaiyesimi, Jennifer S R Mammen, Jarushka Naidoo, Aung Naing, Tanyanika Phillips, Laura D Porter, Cristina A Reichner, Carole Seigel, Jung-Min Song, Alexander I Spira, Maria E Suarez-Almazor, Umang Swami, John A Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S Weber, Kathryn Bollin, Monalisa Ghosh
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (35) (2021)
Yuko Oya, Jeffrey S Weber, Kazuhiro Asada, Tetsuya Oguri, Naoki Inui, Sayako Morikawa, Kentaro Ito, Tomoki Kimura, Eiji Kunii, Takashi Matsui, Akihito Kubo, Tatsuo Kato, Takashi Abe, Takeshi Tsuda, Toyoaki Hida
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. BMC cancer 21 (1) (2021)